Prevagen Supplement

February 2017: Quincy Bioscience moved for an order staying the proceedings in this action pending the resolution of the lawsuit filed against it by the Federal Trade Commission and New York Attorney General in January 2017 (FTC et al v. Quincy Bioscience Holding Co., Inc. et al.).

January 2015:
A class-action lawsuit was filed against Quincy Bioscience, LLC for allegedly misleadingly marketing Prevagen, a brain health supplement. Specifically, the complaint alleges that the supplement is marketed as being “clinically tested” to “improve memory within 90 days” and support “healthy brain function, sharper mind, and clearer thinking” without scientific evidence to support such claims. (Racies et al v. Quincy Bioscience, LLC, Case No. 15-cv-00292, N. D. CA.).

For more information about other class-action lawsuits and TINA.org’s coverage of them, click here.

 

Print Friendly

Tags: ,



Leave a Reply

Back to Top ↑